|1.||Belardinelli, Luiz: 4 articles (01/2013 - 09/2009)|
|2.||Wu, Lin: 3 articles (01/2013 - 09/2009)|
|3.||Shryock, John C: 3 articles (01/2013 - 09/2009)|
|4.||Fossa, Anthony A: 3 articles (08/2008 - 01/2005)|
|5.||Rajamani, Sridharan: 2 articles (01/2013 - 09/2009)|
|6.||Li, Hong: 2 articles (04/2011 - 09/2009)|
|7.||Hong, Charles: 1 article (07/2014)|
|8.||Knollmann, Bjorn C: 1 article (07/2014)|
|9.||Chun, Young Wook: 1 article (07/2014)|
|10.||Mosley, Jonathan D: 1 article (07/2014)|
08/01/1993 - "We evaluated the antiarrhythmic efficacy of E-4031, a new class III drug, and compared it with that of conventional class I and II antiarrhythmic agents in terms of electrophysiological actions on refractoriness and conduction in a 7-day-old canine model of myocardial infarction. "
06/01/1992 - "Posterolateral myocardial infarct sizes, expressed either as percentages of risk area or of total left ventricle, were reduced slightly but not significantly in the E-4031 treatment group compared to the control group (35.2 +/- 5.6 and 45.4 +/- 3.0% of risk area, respectively; 12.7 +/- 2.4 and 17.6 +/- 1.4% of left ventricle, respectively). "
06/01/1990 - "Effects of E-4031, a class III antiarrhythmic agent, on re-entrant ventricular arrhythmias were studied in eight dogs with a 7-day-old myocardial infarction. "
06/01/1990 - "Electrophysiologic effects of E-4031, a class III antiarrhythmic agent, on re-entrant ventricular arrhythmias in a canine 7-day-old myocardial infarction model."
02/01/1991 - "The Class III agent E-4031 was evaluated for its antiarrhythmic and antifibrillatory actions in conscious dogs 3-5 days after anterior myocardial infarction that were responsive to the induction of tachyarrhythmia by programmed electrical stimulation. "
02/01/1996 - "E-4031 reduced the severity of arrhythmias from sustained ventricular tachycardia (VT) to nonsustained VT (7 dogs at 1.0 mg/kg, P = .013 vs. vehicle). "
09/01/2009 - "E-4031 caused spontaneous and pause-triggered polymorphic ventricular tachycardia [torsade de pointes (TdP)]. "
02/01/1991 - "The administration of E-4031 as an intravenous loading dose (100 micrograms/kg) followed by an infusion for 90 min (10 micrograms/kg/min) suppressed the induction of ventricular tachycardia by programmed electrical stimulation in 6 of 12 dogs and prolonged the cycle length of the induced arrhythmia in 5 of the 6 remaining animals. "
06/01/1990 - "These results demonstrated that E-4031 effectively prevented the induction of re-entrant ventricular tachycardia in canine myocardial infarction model, and suggested that E-4031 rendered re-entrant circuits inexcitable by marked ERP prolongation in both normal and infarct zones."
06/01/1990 - "The induction of sustained ventricular tachycardia by programmed electrical stimulation was not suppressed by i.v. infusion of E-4031 at 1 microgram/kg/min, but was suppressed markedly by infusion at 10 micrograms/kg/min in six of seven dogs. "
09/01/2006 - "We concluded that diabetes mellitus reduces the antiarrhythmic effects of flecainide, E-4031, and verapamil."
09/01/2006 - "We designed the present study to examine whether diabetes mellitus affects the antiarrhythmic effect of flecainide, a sodium channel blocker, E-4031, a potassium channel blocker, and verapamil, a calcium channel blocker, in diabetic rats. "
|1.||antineoplaston A10 (A 10)
|4.||Sodium Channels (Sodium Channel)
|5.||Potassium Channels (Potassium Channel)
|6.||Calcium Channels (Calcium Channel)
|7.||Sotalol (Sotalol Hydrochloride)